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Intrinsic or acquired resistance of human tumors to chemotherapy is often
multifactorial. One of the factors involved in resistance is the nuclear enzy-
me DNA topoisomerase ll (Topoll) which is known to be the target of a
variety of cytotoxic drugs which are widely used in the clinic. A factor com-
plicating Topoll research is the presence of two Topoll isoforms in human
cells which are called Topolla and R. In this thesis the role of these iso-
forms in resistance in small cel l  lung carcinoma cell  l ine models is exami-
ned and the regulation of Topoll  expression in human ovarian tumors is
investigated.
In chapter I recent l i terature on human DNA topoisomerase l la and R
and their roles in chemotherapy resistance is extensively reviewed.
Chapter 2 describes the overexpression of the multidrug resistance
associated protein (MRP), drug accumulation defects and downregulation
of Topolla and R mRNA and protein levels with increasing adriamycin
resistance development in GLC. sublines. All  of these resistance mecha-
nisms were already activated in the cell line with the lowest resistance
factor (2-fold) which may be clinically relevant. In a partial revertant (stable
1O-fold resistant) of the most resistant subline (which was 150-fold resis-
tant), the expression of the described resistance mechanisms was interme-
diate. Interestingly, Topolla and R levels were decreased similarly in the
different sublines despite the fact that these isozymes are regulated diffe-
rently during the cell  cycle. In this cel l  l ine panel the decreases in both
isozymes apparently contribute to adriamycin resistance even at clinically
relevant resistance levels.
The mechanism behind the downregulation of Topolla mRNA levels in
the cell  l ine panel found in chapter 2 was analyzed in chapter 3. No chan-
ges in Topolla mRNA half- l i fe, nor genetic rearrangements in the Topolla
gene were found in the most resistant subline. Fluorescence in situ hybrid-
ization using a Topolla gene specif ic probe showed that the parental cel l
l ine GLCo contained a large subpopulation of cel ls with three Topolla gene
copies and a minor subpopulation with only two Topolld gene copies.
Durrng adriamycin resistance development the latter subpopulation was
selected. lt was shown that the gene copy frequency per cell was in agree-
ment with Topollo mRNA- and protein levels. Therefore, i t  was concluded
that gene dosage effects caused by selection for a certain subpopulation,
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contributed importantly to the downregulation of Topolla mRNA- and pro-
tein levels during adriamycin resistance development in this cel l  l ine panel.
In chapter 4 the development and characterization of VM26, mAMSA
and mitoxantrone resistant sublines of GLC. was described. These cell
l ines were developed in order to study resistance mechanisms to Topoll-
drugs other than adriamycin. In none of these cell  l ines overexpression of
P-glycoprotein (P-gp) or MRP was detected, although in the mitoxantrone
resistant subline a small mitoxantrone accumulation defect was found. The
cell  l ines were cross resistant to other Topoll-drugs indicating atypical
mult idrug resistance (see chapter 1), which implicates Topollo or R-related
alterations as contributors to resistance development. The VM26 resistant
subline showed a major decrease in Topolla protein (54o/o of the GLC.
value) and the mAMSA resistant subline a decrease in TopollB protein (to
28Yo). In the mitoxantrone resistant subline the Topolla and R protein levels
were markedly decreased (Topolla to 31%, TopollB protein was undetecta-
ble). The decrease in Topolla protein in the VM26 and the mitoxantrone
resistant sublines was mediated by decreased Topolla mRNA levels. Se-
lection for cells with decreased Topolla gene copies numbers (from 3 to 2)
contributes to the Topolla mRNA decrease in the VM26- and the mitoxan-
trone resistant sublines, just as was shown for the adriamycin resistant
sublines of GLC' (chapter 3). In contrast o the f indings for the adriamycin
resistant cel l  l ines, Topolla and R mRNA and protein levels were decreased
differently. No correlations were found for TopollR mRNA levels and resis-
tance to VM26, mAMSA, fostriecin and mitoxantrone. Negative correlations
were found for Tooollo mRNA levels and resistance to the cleavable com-
plex inducers VM26, mAMSA and mitoxantrone indicating that lower Topol-
la levels may contribute to resistance in the GLC, sublines. The posit ive
correlation found for Topolla mRNA level and fostriecin resistance suggests
that cel ls with lower Topolla levels are more sensit ive to this Topoll  activity
inh ib i tor .
A quantitat ive RT-PCR assay for the determination of Topolla mRNA
levels was described in chapter 5. The assay allows quantitation of very
low amounts of Topolla mRNA in total RNA. GLC. and two resistant subli-
nes were used to validate the assay. The RT-PCR assay quantitates To-
pollo mRNA on picogram level starting with less than 1 ;rg total RNA. The
results obtained by the RT-PCR assay were in agreement with results
obtained by Northern blotting, Western blotting and the Topoll activity
assay indicating that this assay is a useful technique in Topoll  research
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Chapter 7
and Topoll-drug resistance studies.
Chapter 6 describes the characterization of ovarian tumor samples
with regard to several Topoll-related parameters. A correlation was found
for Topolla mRNA levels and Topolla protein levels, and there was almost
a correlation observed for Topoll8 mRNA and protein levels. This suggests
that in these tumors both assays may be used to quantify the level of each
isozyme. Remarkably, TopollR mRNA levels correlated with overall Topoll
activity, while Topollo mRNA levels did not. This might implicate an impor-
tant role for TooollR in ovarian tumors.
PERSPECTIVE
The cell line studies presented in this thesis show that already in cells with
low resistance factors (which are probably clinically relevant) decreases in
Topoll levels may be found. However, as resistance to Topoll drugs is
multifactorial it is very hard to predict how a Topoll decrease contributes to
resistance. An even more complicating finding was that the Topoll gene
copy loss in the mitoxantrone resistant subline, which was in agreement
with the degree of downregulation of Topoll protein, seemed to be caused
by selection of cells displaying gross genetic rearrangements compared
with the parental cel l  l ine. In these cells an entire chromosome 17q arm
was deleted, which is known to carry several oncogenes and tumor sup-
pressor genes, and changes in the level of these genes may also inf luence
the resistance level of a cell. The exact contribution of a Topoll decrease to
resistance may be determined in the future by downregulating Topoll levels
using antisense or r ibozyme techniques or by upregulating Topoll  levels
using gene transfection techniques.
A factor complicating Topoll research is the presence of two Topoll
isozymes in human cells, each having different features. The expression of
these isozymes is regulated differentially during the cell cycle and in resis-
tant cells the expression of each isoform may be affected differently, de-
pending on which drug is used. lt is therefore necessary to gain more
insight in how sensit ive each isoform is for the Topoll  inhibitors which are
used in the clinic. This may be achieved by purification of each isoform and
performing Topoll activity inhibition assays and band depletion assays with
each isozyme. These techniques may shed more light on the importance of
the TopollR isoform, on which only l imited data are available. Addit ionally, i t
cannot be rule
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cannot be ruled out that more Topoll  isoforms wil l  be found in the future.
The cell  l ine models wil l  give more insight in the role of Topoll  chan-
ges in resistance development. However, whether the cell line results can
be extrapolated irectly to tumors is questionable. Therefore, human tumor
material has to be screened and reliable assays have to be developed
which are able to quantify Topoll levels even when only very little tumor
material (e.g. f ine needle biopsies) is available. When certain assays are
not applicable to biopsy material, short term tumor cultures may have to be
used. These assays will give more information on Topoll levels regarding
tumor types, but also on Topoll status within each tumor type and within
each tumor. Ultimately, it may become necessary to estimate the amount of
each isozyme present within a tumor in order to predict which Topoll  drugs
may have to be used.
Also the genetic background of a tumor with respect to other genes
may be important. When the tumor lacks the genetic material which is
necessary for a cell to die from a certain drug according to a certain pro-
grammed cell  death route (e.9. VP16 induces apoptosis), these drugs may
be useless in this specif ic tumor.
Even more intr iguing is the idea to change the tumor in such a way
that it will die from Topoll drugs more efficiently. When in the future Topoll-
specific transcription factors are found or genes whose products can modify
Topoll activity, i t  may become possible to upregulate Topoll  levels or activi-
ty in a tumor to make it  more sensit ive to Topoll  cleavable complex indu-
cers, or to downregulate Topoll levels to make it more sensitive to Topoll
activity inhibitors. Of course, transfection with the Topoll genes themselves
may already be sufficient for these purposes. Also the genetic background
regarding cell death routes may be altered when tumor specific gene thera-
py becomes possible. An even more complicated strategy may involve
stimulation of the processes which take place at DNA level (such as trans-
cript ion and replication) which are probably causing DNA damage and cell
death when Topoll molecules are fixed on the DNA after treatment with
cleavable complex inducers.
summarizing, the Topoll  status of a tumor could be an important
predictive factor for the sensitivity of a tumor for Topoll targeting drugs.
However, the relative sensitivities of both Topoll isozymes are not known at
present and have to be clarified. When Topoll-isozyme specific transcripti-
on factors are found, each isozyme may be specifically upregulated, thus




strategy involves the enhancement of Topoll activity. Finally, it may be
attempted to stimulate the processes which are involved in cell death
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